The goal of this clinical research study is to learn if Sutent® (sunitinib malate, SU011248)
can control the disease in patients with germ cell tumors that are resistant to earlier
Drug: Sunitinib Malate
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT00912912
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Progressive metastatic Germ-cell tumors (GCTs) of gonadal or extragonadal origin in males after failure of front-line therapy and at least one salvage regimen.
Must have evaluable or measurable disease by clinical or radiological studies. Alternatively, in the absence of radiologically evaluable or measurable disease, two sequentially rising marker values each one week apart attributed by treating physician to germ cell tumor is permitted; either beta human chorionic gonadotropin (hCG) above 50 mIU/ml and/or alpha-fetoprotein (AFP) above 20 ng/ml qualifies as eligible.
The Eastern Cooperative Oncology Group (ECOG) Performance Score 0-2
Adequate organ function as follows: Calculated creatinine clearance >/= 35cc/min, Absolute neutrophil count >/= 1500/mm^3, hemoglobin >/= 8 g/dL, serum calcium </= 12 mg/dL, Platelet count >/= 75,000/mm^3, AST (SGOT)/ALT (SGPT) < 2.5 x upper limit of normal (ULN), Total bilirubin < 2.0mg/dl.
Resolution of all acute toxic effects of prior chemotherapy or radiotherapy or surgical procedures to NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 grade </= 2.
At least 18 years of age as safety of sunitinib in a pediatric population has not been established.
Able to provide informed consent
Must be able to ingest oral medication
Male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
Patients who have not received prior high-dose chemotherapy and stem cell rescue as salvage therapy will have this option discussed with them. Only patients ineligible, unwilling or unable to undertake this option will be eligible for this trial.
NCI CTCAE Version 3.0 grade 3 hemorrhage within the 4 weeks prior to starting the study treatment.
Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
Patients with history of Long QT syndrome.
Ongoing cardiac dysrhythmias of NCI CTCAE Version 3.0 grade >/= 2.
Uncontrolled Hypertension (> 140/90 mm Hg despite optimal medical therapy).
Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication.
Symptomatic bowel obstruction.
Prior VEGFR/PDGFR inhibitor therapy.
Known human immunodeficiency virus infection, chronic active hepatitis or liver cirrhosis.
All locations for NCT00912912
United States (1)
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Trial results for NCT00912912
Participant Flow: Overall Study
1 / 5
Completed / Started
Serious Adverse Events
3 / 5
Affected / At Risk
Other Adverse Events
5 / 5
Affected / At Risk
View full eligibility
Tris trial is registered with FDA with number: NCT00912912. The sponsor of the trial is M.D. Anderson Cancer Center and it is looking for 5 volunteers for the current phase.
Official trial title: Phase II Study of Sunitinib Malate in Refractory Germ Cell Tumors
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
Consult your doctor?
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.